Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? by Barbara Zabłocka et al.
OPINION ARTICLE
published: 01 November 2012
doi: 10.3389/fendo.2012.00131
Mechano-Growth Factor: an important cog or a loose screw
in the repair machinery?
Barbara Zabłocka1, Paul H. Goldspink2, Geoffrey Goldspink3 and Dariusz C. Górecki4*
1 Molecular Biology Unit, Mossakowski Medical Research Centre PAS, Warsaw, Poland
2 Department of Physiology and Cardiovascular Center, Medical College of Wisconsin, WI, USA
3 Professor Emeritus, Department of Surgery and Interventional Medicine, University College London, London, UK
4 Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth, UK
*Correspondence: darek.gorecki@port.ac.uk
Edited by:
Ronald W. Matheny, United States Army Research Institute of Environmental Medicine, USA
Reviewed by:
Ronald W. Matheny, United States Army Research Institute of Environmental Medicine, USA
Insulin-like growth factor I (IGF-1) is
an important peptide synthesized in
response to growth hormone stimulation.
Alternative promoters and an elaborate
alternative splicing regulated in a tissue-
and developmentally-specific manner
result in the production of several distinct
isoforms of IGF-1 [reviewed in Gorecki
et al. (2007); Matheny et al. (2010)]. The
predominant form, IGF-1Ea is a circu-
lating factor produced in the liver while
IGF-1Eb and IGF-1Ec (Mechano-Growth
Factor, MGF) are expressed in specific tis-
sues in response to different, often patho-
logical stimuli and appear to have some
specific functions in these different tissues
[reviewed in Aberg et al. (2006); Gorecki
et al. (2007); Matheny et al. (2010)].
Unfortunately, the initial naming of
these specific isoforms caused some con-
fusion (Matheny et al., 2010), mainly
because 3′-end splicing in rodents and
humans results in slightly different read-
ing frames and also due to the over-
lapping naming of the synthetic peptide
domains (see below). We have consis-
tently adopted the designations suggested
in Hameed et al. (2003). Thus, the main
human transcript (IGF-1Ea) has exon 4
spliced directly to exon 6. Inclusion of
exon 5 results in two transcript variants:
IGF-1Ec (also designated MGF) contains
part of exon 5 spliced to exon 6, which
results in a frame-shift and this mRNA is
translated into an isoform with alterna-
tive 25 amino acids at the C-terminus. The
third transcript variant (IGF-1Eb) extends
further downstream of exon 5 but only the
first 17 amino acids of this isoform are
identical with those in the IGF-1Ec peptide
(Siegfried et al., 1992).
IGF-1 isoforms are produced as a
preprohormone containing a signal pep-
tide at the amino-terminus. Removal
of the signal peptide leaves the prohor-
mone (mature peptide + E-domain),
which is further cleaved to yield the
mature peptide (70 amino acids) and
the E-domain. Cleavage of the E-domain
region occurs at a pentabasic-processing
motif LysXXLys68XXArg71XXArgXXArg
between the D and E-domains (Duguay
et al., 1995). Disruption of this cleavage
site does not impact secretion per se, but
appears to modulate the activities and
actions of the mature IGF-1 (Pfeffer et al.,
2009; Barton et al., 2010). Interestingly,
the existence of the different E-domain
regions gives rise to unique isoform-
specific gene expression profiles compared
to those associated with mature IGF-1
(Barton et al., 2010). These data suggest
the E-domains regulate aspects of IGF-1
actions whether in the prohormone form
or independently upon cleavage. Given
the existence of this cleavage site in all
the isoforms and disruption modifies
behavior, it is reasonable to hypothesize
that the E-domain may have independent
actions in vivo. Indeed, research to date
has been directed at defining those actions
in relation to MGF and the use of pep-
tide mimetics have been insightful (see
below).
Specific actions of IGF-1 isoforms have
been identified in different tissues, includ-
ing development, growth, repair, and
maintenance of muscles. Skeletal muscle
is a post mitotic tissue and cell division
does not take place within muscle fibers
once they are formed. During post-natal,
post-damage and exercise-induced muscle
growth the proliferating cells (myoblasts)
required for these processes originate from
the pool of muscle stem (satellite) cells.
IGF-1 stimulates differentiation and, to
a lesser degree, proliferation in cultured
primary satellite cells. There is evidence
of an autocrine/paracrine stimulation via
IGF-1 (Goldspink, 2004; Hameed et al.,
2004; Mourkioti and Rosenthal, 2005).
Skeletal muscle stretch/overload results in
the increase of the IGF-1 mRNA, partic-
ularly its specific IGF-1Ec (MGF) vari-
ant. In this system the specific effects of
the synthetic E-domain peptide mimetic
have been shown: satellite cells are acti-
vated to replicate by the MGF-24aa-E
peptide (YQPPSTNKNTKSQRRKGSTFE-
EHK) (Kandalla et al., 2011) and they are
prevented from going further until they
fuse with the muscle fibers and when they
adopt a myogenic program (Qin et al.,
2012). During ageing, muscle produces
less MGF transcript but if it is provided to
myoblasts cultures taken from biopsies of
muscle from an elderly person, these mus-
cle cells are still able to replicate (Kandalla
et al., 2011).
In the heart, there is temporal regu-
lation of both MGF and IGF-IEa mRNA
expression in response to ischemia associ-
ated myocardial infarction. MGF expres-
sion is induced within one hour and
remains elevated for up to 8 weeks
whereas the IGF-Ea appears after 4 days
(Stavropoulou et al., 2009). These expres-
sion profiles suggest that the isoforms play
distinct and separable roles in local adap-
tation aimed at mitigating tissue dam-
age to augment cardiac output. Moreover,
intracoronary delivery of the MGF-24aa-E
peptide elicits myocardial protection and
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improves hemodynamic function to a
greater extent than mature IGF-1 follow-
ing myocardial infarction in sheep. As the
analog does not have the IGF-1 recep-
tor (IGF-1R) binding site, the mechanisms
of action may differ (see below). Limited
mechanistic findings suggested that the
cellular protection conferred by the MGF-
24aa-E peptide, was due to an inhibition
of apoptosis in the infarct border zone
(Carpenter et al., 2008). However, given
the growing data showing effects of the
MGF-24aa-E peptide on various precur-
sor cell populations, it is an intriguing
notion to speculate that similar effects
may exist on cardiac precursor cell pop-
ulations to aid in repair and recovery
of the heart. It is well known the heart
has a limited capacity for regeneration,
but recent studies have shown the exis-
tence of resident populations of multi-
potent precursor cells (Segers and Lee,
2008). These cells exist in extremely low
numbers but if stimulated, could provide
an endogenous source for the different
lineages (cardiac, endothelia, and vascu-
lar) needed to initiate regeneration. To
this end, the MGF-24aa-E peptide has
been shown to increase proliferation and
migration of mesenchymal bone marrow
derived stem cells, which have been pro-
posed as a source of autologous stem
cells for transplantation into the heart
(Collins et al., 2010). In addition, the
MGF-24aaE peptide appears to stimulate
pro-angiogenic activities in human vascu-
lar endothelial cells (Deng et al., 2012).
Thus, delivery of the MGF-24aa-E peptide
could bestow potentially useful therapeu-
tic actions at the level of vascular regenera-
tion and collateralization, to restore blood
flow in the heart following myocardial
infarction.
Similarly, specific IGF-1 isoforms are
important factors for brain development
and function, are expressed in response to
different types of injury and can reduce
neuronal death (Dluzniewska et al., 2005;
Beresewicz et al., 2010). Again, while
both IGF-1Ea and IGF-1Ec (MGF) tran-
scripts have been shown expressed dur-
ing brain development, they show highly
specific temporal distributions. Moreover,
neonatal hypoxia and hypoxia-ischemia
insults produce increased and prolonged
expression of the IGF-1Ec (MGF) iso-
form only (Beresewicz et al., 2010).
Furthermore, MGF but not IGF-1Ea was
found overexpressed in the regenerat-
ing regions following global adult brain
ischemia. In this model, the MGF-24aa-E
peptide has also shown specific effects
independent from the IGF-1R stimulation
(Dluzniewska et al., 2005).
Furthermore, IGF-1 plays a complex
role at the interface between neurons
and the injured or damaged muscle. In
a model of amyotrophic lateral sclero-
sis (ALS), a disease with loss of motor
neurons and progressive muscle weakness,
muscle overexpression of IGF-1 slowed the
disease progression (Dobrowolny et al.,
2005). While treatment with either full-
length IGF-I or MGF expressing con-
structs resulted in improvements in this
mouse model, significantly more motor
neurons survived in MGF-treated mice
(Riddoch-Contreras et al., 2009). While
clinical trials with IGF-1 gave conflict-
ing results, recent data indicate that this
treatment might be effective in patients
with less severe phenotypes (Saenger et al.,
2012).
Mature IGF-1 acts via the IGF-1R.
Binding induces phosphorylation of
the receptor and activates the down-
stream effector cascades involving the
MAP kinase, cyclin D, cdk4, c-fos,
c-jun, calcium–calmodulin-dependent
kinase and, via PI3-K, Akt pathways
downstream effector genes. In addi-
tion, IGF-1 activity is modulated by its
binding proteins (IGFBPs) and autoregu-
latory feedback loops aimed at regulating
receptor mediated signaling. The afore-
mentioned differential effects of IGF-1
isoforms appear to stem from the fact
that the actions of the E-domains can
be separated from receptor activation
and show preferences with respect to
the signal transduction pathways. This
further supports the notion that syn-
thetic equivalents of the E domains may
function as independent biologically
active peptides. Unfortunately, still lit-
tle is known about the mechanism(s)
of action and wider biological effects of
these short peptides but data are start-
ing to indicate distinct pathways may
be involved. In case of the MGF-24aa-E
peptide, one recent study demonstrated
that PKC activity is needed for this pep-
tide activation (translocation to nucleus)
of NF-E2-related factor-2 (Nrf2), which
in turn increases heme oxygenase-1
expression, a critical event in mediating
neuroprotection of neurons from oxida-
tive stress-induced apoptosis (Quesada
et al., 2011). In another models, the
MGF-24aa-E peptide appears to stimu-
late the MAPK\ERK-signaling pathway
(Stavropoulou et al., 2009; Deng et al.,
2012).
In view of the difference in their modes
of action it appears possible to separate
the broad activity of the mature IGF-1
peptide from the protective and pro-
regenerative effects of its E-domain deriva-
tives. Moreover, small peptides show good
tissue penetration, can be inexpensively
manufactured and modified to increase
their stability. They are therefore good
candidates for development into a thera-
peutic modality and, not surprisingly, such
compounds attract attention of pharma-
ceutical industry.
Intriguingly, the MGF-24aa-E peptide
has attracted considerable attention, but
not from the mainstream pharmaceuti-
cal industry or the medical establishment
but instead from the poorly regulated
or outright illegal branches of pharma:
the MGF-24aa-E peptide has become an
important component of the readily avail-
able anabolic and doping products and
there may be a number of reasons for this
peculiar situation.
Firstly, there is controversy surround-
ing the endogenous production of short
E-domain peptides. While the full length
IGF-1Ec isoform has been identified using
E-domain-specific antibodies in various
experimental settings, the existence of
the endogenously functioning E peptides
has not been confirmed despite the fact
that the equivalent synthetic E-domain
peptide is effective (Tan et al., 2002;
Dluzniewska et al., 2005). It could be
therefore argued that the effects of the
MGF-24aa-E mimetic are not related to
the prohormone form containing this
E domain. However, considering that
endogenous expression of this isoform
has been identified in specific tissues
in which MGF-24aa-E peptide is effi-
cacious, it seems an unlikely coinci-
dence. Nevertheless, it does not clarify
whether the endogenous E domain exerts
its function as a prohormone before it
is further cleaved into the mature IGF-1
peptide and the E-domain. Closely linked
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with this issue is the very important
and still unanswered question of the
mechanism of action of the E-domain
and its peptide mimetics. All we really
know is that it does not require the
canonical binding site of the IGF-1R.
This is supported by recent studies using
the MGF-24aa-E peptide showing that
the putative site of action of the MGF
E-domain region maybe at the level
of the nucleus (Quesada et al., 2011;
Schönenberger et al., 2011; Peng et al.,
2012). These data would further support
cleavage of the E-domain region in vivo
and its targeting to the nucleus, where
it might exert intracrine actions to mod-
ify the canonical IGF-1 signaling via it’s
receptor at the cell membrane. This effect
is not uncommon in the peptide hormone
and growth factor family (Re and Cook,
2011).
In addition, the difficulty with iden-
tifying these short peptides may stem
from the fact that molecules of IGF-
1 aggregate at pH close to its iso-
electric point (Torrado and Carrascosa,
2003) and this covalent aggregation is
one of its main degradation pathways.
If such aggregation involves the short
E-domain peptides it could mask their
presence in tissues. Moreover, studies
with various synthetic E-domains have
shown that they benefit from chemi-
cal stabilisation (Collins et al., 2010)
and thus their endogenous equivalents
are predicted to have a very short half-
life. In fact they may be active at
very low concentrations functioning in
an autocrine/paracrine/intracrine fashion
which would be expected for growth
factors in the physiologic environment,
further complicating detection of their
endogenous processing.
Clearly more research is needed.
But MGF seems to be a highly under-
researched subject, particularly if one
considers the likely applications of
MGF in diseases with a great socioe-
conomic impact in aging populations
(e.g., cardiovascular, sarcopenia, and neu-
rodegeneration). This probably reflects
the complexities of biopharmaceuti-
cals development. These products, by
the very nature of their origins face
specific problems in terms of manufacture,
storage, quantifiable standardization
and, finally, their approval. This is
usually associated with higher costs when
compared with small molecule drugs.
Industry often finds these costs unac-
ceptable when facing possible patent
right challenges based on slightly mod-
ified biosimilars and rapid emergence
of market competition following patent
expiry.
In an astonishing contrast, the MGF
has been welcomed and widely accepted
by the body building industry and numer-
ous fitness enthusiasts. Body builders use
this peptide alone or in combination with
other anabolic compounds. Perfunctory
survey of various discussion fora1 makes
a chilling read for anybody who knows
how little is yet known about the MGF.
Detailed advice on administration regimes
contains a mixture of in depth scrutiny
of scientific literature and a hear-say fol-
lowing self-administration. Although its
function is not fully understood and its
efficacy in man is not proven, MGF is
seen as a powerful tool to gain perfor-
mance (Bachl et al., 2009). It is not surpris-
ing that the World Anti-Doping Agency
has banned the use of MGF in sports.
Recent study reporting MGF detection
in two black market products (Esposito
et al., 2012) clearly confirmed that MGF
preparations are commercially available
for use as doping. Even more ominously,
illegal production of MGF mimetics and
attempts to bypass the WADA ban may
result in generation of analogs of unknown
properties and potentially serious side
effects.
The existence of IGF’s has been stud-
ied for over five decades, when they
have evolved as being growth hor-
mone inter-mediators, endocrine, and
autocrine/paracrine factors. This com-
plex system, which is preserved through
the vertebrate phylogeny, influences a
remarkable array of cellular and organ-
ismal functions. Consequently, it may
not be too surprising that additional
levels of regulation and isoform func-
tion may exist due to the presence of the
different E-domain regions in the splice
variants and as such, present new chal-
lenges to fully understanding how the
IGFs’ work.
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